Rapid regression of atherosclerosis: insights from the clinical and experimental literature.
Looking back at animal and clinical studies published since the 1920s, the notion of rapid regression and stabilization of atherosclerosis in humans has evolved from a fanciful goal to one that might be achievable pharmacologically, even for advanced plaques. Our review of this literature indicates that successful regression of atherosclerosis generally requires robust measures to improve plasma lipoprotein profiles. Examples of such measures include extensive lowering of plasma concentrations of atherogenic apolipoprotein B (apoB)-lipoproteins and enhancement of 'reverse' lipid transport from atheromata into the liver, either alone or in combination. Possible mechanisms responsible for lesion shrinkage include decreased retention of apoB-lipoproteins within the arterial wall, efflux of cholesterol and other toxic lipids from plaques, emigration of foam cells out of the arterial wall, and influx of healthy phagocytes that remove necrotic debris and other components of the plaque. Unfortunately, the clinical agents currently available cause less dramatic changes in plasma lipoprotein levels, and, thereby, fail to stop most cardiovascular events. Hence, there is a clear need for testing of new agents expected to facilitate atherosclerosis regression. Additional mechanistic insights will allow further progress.
Williams
Kevin Jon
KJ
Department of Medicine/Division of Endocrinology, Thomas Jefferson University, Philadelphia, PA 19107, USA. k_williams@mail.jci.tju.edu
Feig
Jonathan E
JE
Fisher
Edward A
EA
D000818:Animals; D050197:Atherosclerosis / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018752:Diet, Fat-Restricted; D004195:Disease Models, Animal; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects / Q000235:genetics; D051379:Mice; D011323:Primates; D011817:Rabbits; D012074:Remission Induction; D013552:Swine; D016896:Treatment Outcome
D002317:Cardiovascular Agents